Literature DB >> 9230790

Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria.

S Looareesuwan1, P Wilairatana, C Viravan, S Vanijanonta, P Pitisuttithum, D E Kyle.   

Abstract

One hundred fifty-one patients with acute uncomplicated falciparum malaria were enrolled in a randomized, open-label study of oral artemether given alone for five or seven days or a sequential treatment of oral artemether followed by mefloquine. Forty patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 500 mg over a five-day period: Group I. Fifty-eight patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 750 mg over a seven-day period: Group II. Fifty-three patients received oral artemether, 200 mg every 8 hr for a total dose of 600 mg, followed 8 hr later with mefloquine (1,250 mg divided into two doses given 6 hr apart: Group III. All patients were admitted to the hospital for 28 days to exclude reinfection and 131 patients remained through the 28-day follow-up. Only two, nine, and nine patients in Groups I, II, and III, respectively, left the hospital prior to study completion for reasons unrelated to their treatment. Cure rates for the three groups were 74% (28 of 38) for Group I, 98% (48 of 49) for Group II, and 98% (43 of 44) for Group III. Mean fever and parasite clearance times were not significantly different (32.8, 27.5, and 31.4 hr for fever clearance times and 40.2, 40.6, and 36.7 hr for parasite clearance times of Groups I, II, and III, respectively) nor were any adverse effects seen. In vitro drug susceptibility testing of admission and recrudescent parasite isolates was conducted for 10 patients. These data showed no decreased response to artemether or dihydroartemisinin in recrudescent isolates when compared with admission isolates. The results of this study suggest that sequential treatment for two days with oral artemether (600 mg) followed by mefloquine (1,250 mg) is effective and well-tolerated in patients with acute uncomplicated falciparum malaria and may be an alternative treatment for multidrug-resistant falciparum malaria, particularly useful for treating patients in rural areas where the period of admission to the hospital should be as short as possible. A seven-day regimen of artemether alone (750 mg) is also very effective, yet requires prolonged administration of drug after malaria symptoms disappear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230790     DOI: 10.4269/ajtmh.1997.56.613

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Blood-stage dynamics and clinical implications of mixed Plasmodium vivax-Plasmodium falciparum infections.

Authors:  D P Mason; F E McKenzie
Journal:  Am J Trop Med Hyg       Date:  1999-09       Impact factor: 2.345

2.  In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genes.

Authors:  Carolina Bustamante; Onikepe A Folarin; Grace O Gbotosho; Camila N Batista; Elieth A Mesquita; Rodrigo M Brindeiro; Amilcar Tanuri; Claudio J Struchiner; Akintunde Sowunmi; Ayoade Oduola; Dyann F Wirth; Mariano G Zalis; Christian T Happi
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

Review 3.  Artemisinin derivatives for treating uncomplicated malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum.

Authors:  Matthew S Tucker; Tina Mutka; Kansas Sparks; Janus Patel; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  Can treatment of P. vivax lead to a unexpected appearance of falciparum malaria?

Authors:  D P Mason; S Krudsood; P Wilairatana; P Viriyavejakul; U Silachamroon; W Chokejindachai; P Singhasivanon; S Supavej; F E McKenzie; S Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2001-03       Impact factor: 0.267

Review 6.  Management of malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Nanthaphorn Phophak; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2002-03       Impact factor: 1.341

7.  Recent Advances in the Prophylaxis and Treatment of Malaria.

Authors:  Annie-Claude Labbé; Mona R. Loutfy; Kevin C. Kain
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

8.  Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Suparp Vannaphan; Sombat Treeprasertsuk; Udomsak Silachamroon; Weerapong Phomrattanaprapin; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-03       Impact factor: 0.267

9.  Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy?

Authors:  Qin Cheng; Dennis E Kyle; Michelle L Gatton
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-27       Impact factor: 4.077

10.  Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure.

Authors:  Philip Bejon; George Warimwe; Claire L Mackintosh; Margaret J Mackinnon; Sam M Kinyanjui; Jennifer N Musyoki; Peter C Bull; Kevin Marsh
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.